Auryx Raises $2 Million to Turn Earbuds into Continuous Health Monitors

Context The wearable market relies heavily on optical sensors that shine light onto the skin to infer blood flow. Those sensors struggle with motion artefacts, especially on the wrist. Auryx’s founders, a team of University of Cambridge researchers, argue that the ear offers a more stable acoustic environment. By repurposing the microphones already present in consumer earbuds, they can listen to the subtle sounds of the heart, lungs and blood vessels and translate them into clinical‑grade metrics.

Key Facts - The company raised $2 million in pre‑seed funding, led by Celero Ventures with participation from EWOR, Cambridge Enterprise Ventures, Vento, PurposeTech and other investors. - CEO Erika Bondareva says the goal is to make health monitoring “just happen” by turning everyday wearables into continuous sensors. - Acoustic sensing captures a broader set of signals than optical wearables, including heart rate, respiratory rate, cardiac output (the volume of blood the heart pumps per minute) and blood pressure. - The technology leverages existing in‑ear microphones, eliminating the need for additional hardware or user intervention. - Initial focus is on the earbud market, which already reaches hundreds of millions of users, with plans to expand to any device equipped with a microphone.

What It Means If Auryx’s platform scales, users could receive real‑time cardiovascular data while listening to music or podcasts, without wearing a dedicated medical device. Continuous monitoring of blood pressure and cardiac output could enable earlier detection of hypertension or heart failure, conditions that often go unnoticed until symptoms appear. The ear’s relative stability reduces motion noise, potentially delivering more reliable readings than wrist‑based trackers.

The $2 million will fund hardware integration, machine‑learning model refinement, commercial partnerships and team expansion. As the company hires engineers and business staff, the next milestone will be a pilot program with a major earbud manufacturer. Success there could accelerate adoption across billions of devices, turning ordinary listening experiences into health‑aware interactions.

What to watch next: Auryx’s first commercial demo and any partnership announcements with leading earbud brands will indicate how quickly acoustic health monitoring could move from lab to mainstream.